Vertigo is a sensation of movement when no movement is actually occurring. It is often accompanied by visceral autonomic symptoms including pallor, diaphoresis, nausea, and vomiting. Vertigo is similar to motion sickness in that both may be caused by vestibular stimulation that does not match an internal model of expected environmental stimuli. Indeed, a functioning vestibular system is necessary for the perception of motion sickness. For this reason, many of the same drugs are used to treat both conditions. The investigation of drugs that treat motion sickness helps to discover medications that may treat vertigo caused by disease of the vestibular system. In this article, we discuss the pharmacologic agents that are now available for the treatment of vertigo and those agents that are still under study.
References
1.
HargreavesJ.A double-blind placebo controlled study of cinnarizine in the prophylaxis of seasickness. Practitioner1980;224:547–50.
2.
WoodCD, GraybielA.Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions. Aerosp Med1968;39:1341–4.
3.
BarberHO, BasserW, JohnsonWH, TakahashiP.The laboratory assessment of anti-motion sickness and anti-vertigo drugs. Can Med Assoc J1967;97:1460–5.
4.
CramptonGH, ed. Motion and Space Sickness. Boca Raton, Fla.: CRC Press, 1990.
5.
CheungBS, MoneyKE, KohlRL, KinterLB. Investigation of anti-motion sickness drugs in the squirrel monkey. J Clin Pharmacol1992;32:163–75.
6.
ZajoncTP, RolandPS. Vertigo and motion sickness. Part I: Vestibular anatomy and physiology. Ear Nose Throat J2005;84:581–4.
7.
SekitaniT, McCabeBF, RyuJH. Drug effects on the medial vestibular nucleus. Arch Otolaryngol1971;93:581–9.
8.
McClureJA, LycettP, BaskervilleJC. Diazepam as an anti-motion sickness drug. J Otolaryngol1982;11:253–9.
9.
MarillKA, WalshMJ, NelsonBK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: A randomized clinical trial. Ann Emerg Med2000;36:310–19.
10.
JohnsonGD. Medical management of migraine-related dizziness and vertigo. Laryngoscope1998;108:1–28.
11.
TimmermanH.Pharmacotherapy of vertigo: Any news to be expected? Acta Otolaryngol Suppl1994;513:28–32.
12.
WoodCD, CramerDB, GraybielA.Antimotion sickness drug efficacy. Otolaryngol Head Neck Surg1981;89:1041–4.
13.
MuthER, JokerstM, SternRM, KochKL. Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced motion sickness. Aviat Space Environ Med1995;66:1041–5.
14.
DahlE, Offer-OhlsenD, LillevoldPE, SardvikL.Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther1984;36:116–20.
15.
KohlRL, CalkinsDS, RobinsonRE. Control of nausea and autonomic dysfunction with terfenadine, a peripherally acting antihistamine. Aviat Space Environ Med1991;62:392–6.
16.
TurnerJSJr, JacksonRT. Astemizole: Its use in patients with chronic vertigo and ENG signs—a pilot study of a new drug. Laryngoscope1983;93:898–902.
17.
JacksonRT, TurnerJSJr.Astemizole. Its use in the treatment of patients with chronic vertigo. Arch Otolaryngol Head Neck Surg1987;113:536–42.
18.
KohlRL, HomickJL, CintronN, CalkinsDS. Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man. Aviat Space Environ Med1987;58:1171–4.
19.
WoodCD, StewartJJ, WoodMJ, MimsM.Effectiveness and duration of intramuscular antimotion sickness medications. J Clin Pharmacol1992;32:1008–12.
20.
LacknerJR, GraybielA.Use of promethazine to hasten adaptation to provocative motion. J Clin Pharmacol1994;34:644–8.
21.
WoodCD, MannoJE, MannoBR, Evaluation of antimotion sickness drug side effects on performance. Aviat Space Environ Med1985;56:310–16.
22.
WoodCD, GraybielA.The antimotion sickness drugs. Otolaryngol Clin North Am1973;6:301–13.
23.
PedigoNWJr, BrizzeeKR. Muscarinic cholinergic receptors in area postrema and brain stem areas regulating emesis. Brain Res Bull1985;14:169–77.
24.
van MarionWF, BongaertsMC, ChristiaanseJC, Influence of transdermal scopolamine on motion sickness during 7 days’ exposure to heavy seas. Clin Pharmacol Ther1985;38:301–5.
25.
ParrottAC. Transdermal scopolamine: A review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med1989;60:1–9.
26.
ParrottAC. Transdermal scopolamine: Effects of single and repeated patches upon aspects of vision. Hum Psychopharmacol1986;3:27–41.
NorfleetWT, DegioanniJJ. CalkinsDS, Treatment of motion sickness in parabolic flight with buccal scopolamine. Aviat Space Environ Med1992;63:46–51.
32.
StorperIS, SpitzerJB, ScanlanM.Use of glycopyrrolate in the treatment of Meniere's disease. Laryngoscope1998;108:1442–5.
33.
LucotJB, van CharldorpKJ, TulpMT. Idaverine, an M2- vs. M3-selective muscarinic antagonist, does not prevent motion sickness in cats. Pharmacol Biochem Behav1991;40:345–9.
34.
GoldingJF, StottJR. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol1997;43:633–7.
35.
DowdyEG, GoksenN, ArnoldGE, A new treatment of Meniere's disease. Arch Otolaryngol1965;82:494–7.
36.
GatesGA. Innovar treatment for Meniere's disease. Acta Otolaryngol1999;119:189–93.
37.
JohnsonWH, FentonRS, EvansA.Effects of droperidol in management of vestibular disorders. Laryngoscope1976;86:946–54.
38.
IrvingC, RichmanPB, KaiafasC, Droperidol for the treatment of acute peripheral vertigo. Am J Emerg Med1999;17:109–110.
39.
SlatteryWHIII, FayadJN. Medical treatment of Meniere's disease. Otolaryngol Clin North Am1997;30:1027–37.
40.
MillerJD, BrizzeeKR. The anti-emetic properties of 1-sulpiride in a ground-based model of space motion sickness. Life Sci1987;41:1815–22.
41.
MyersFH. Anticonvulsant drugs. In: MyersFH, JawetzE, GoldfineA, eds. Review of Medical Pharmacology. 4th ed. Los Altos, Calif.: Lange Medical Publications, 1974;298–307.
42.
ChelenW, KabriskyM, HatsellC, Use of phenytoin in the prevention of motion sickness. Aviat Space Environ Med1990;61:1022–5.
43.
SternRM, UijtdehaageSH, MuthER, KochKL. Effects of phenytoin on vection-induced motion sickness and gastric myoelectric activity. Aviat Space Environ Med1994;65:518–21.
44.
LeeJA, WatsonLA, BoothbyG.Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med1986;57:45–8.
45.
SchmidtR, OestreichW.Flunarizine in the treatment of vestibular vertigo: Experimental and clinical data. J Cardiovasc Pharmacol1991;18(suppl 8):S27–30.
46.
PfaltzCR, AoyagiM.Calcium-entry blockers in the treatment of vestibular disorders. Acta Otolaryngol Suppl1988;460:135–42.
47.
WoodCD, GraybielA.Theory of antimotion sickness drug mechanisms. Aerosp Med1972;43:249–52.
48.
CasucciG, Di CostanzoA.RivaR, Central action of cinnarizine and flunarizine: A saccadic eye movement study. Clin Neuropharmacol1994;17:417–22.
49.
ShupakA, DoweckI, GordonCR, SpitzerO.Cinnarizine in the prophylaxis of seasickness: Laboratory vestibular evaluation and sea study. Clin Pharmacol Ther1994;55:670–80.
50.
RascolO, HainTC, BrefelC, Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs1995;50:777–91.
51.
DarlingtonCL, SmithPF. Drug treatment for vertigo and dizziness. NZ Med J1998;111:332–4.
52.
LassenLF, HirschBE, KamererDB. Use of nimodipine in the medical treatment of Meniere's disease: Clinical experience. Am J Otol1996;17:577–80.
53.
MarleyJE, JoyMD. Alleviation of motion sickness by nifedipine [letter]. Lancet1987;2:1265.
54.
TakedaN, MoritaM, YamatodaniA, Catecholaminergic responses to rotational stress in rat brain stem: Implications for amphetamine therapy of motion sickness. Aviat Space Environ Med1990;61:1018–21.
55.
KohlRL, LewisMR. Mechanisms underlying the antimotion sickness effects of psychostimulants. Aviat Space Environ Med1987;58:1215–18.
56.
KohlRL, CalkinsDS, MandellAJ. Arousal and stability: The effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness. Aviat Space Environ Med1986;57:137–43.
57.
McMillanBA. CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol Sci1983;4:429–32.
58.
KohlRL, SandozGR, ReschkeMF, Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine. J Clin Pharmacol1993;33:1092–1103.
59.
FreemanAJ, BountraC, DaleTJ, The vomiting reflex and the role of 5-HT3 receptors. Anticancer Drugs1993;4(suppl 2):9–15.
60.
YatesBJ, MillerAD, LucotJB. Physiological basis and pharmacology of motion sickness: An update. Brain Res Bull1998;47:395–406.
61.
LucotJB, CramptonGH. Buspirone blocks motion sickness and xylazine-induced emesis in the cat. Aviat Space Environ Med1987;58:989–91.
62.
LucotJB. Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats. Pharmacol Biochem Behav1990;37:283–7.
63.
LucotJB. Antiemetic effects of flesinoxan in cats: Comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin. Eur J Pharmacol1994;253:53–60.
64.
BiverF, GoldmanS, LuxenA, Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med1994;21:937–46.
65.
OkadaF, SaitoH, MatsukiN.Blockade of motion- and cisplatininduced emesis by a 5-HT2 receptor agonist in Suncus murinus. Br J Pharmacol1995;114:931–4.
66.
OkadaF, SaitoH, MatsukiN.Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus. Eur J Pharmacol1996;309:33–5.
67.
WildeMI, MarkhamA.Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs1996;52:773–94.
68.
StottJR, BarnesGR, WrightRJ, RuddockCJ. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol1989;27:147–57.
69.
GardnerCJ, TwissellDJ, DaleTJ, The broad-spectrum antiemetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol1995;116:3158–63.
70.
BeattieDT, BeresfordIJ, ConnorHE, The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol1995;116:3149–57.
71.
ReidK, PalmerJL, WrightRJ, Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol2000;50:61–4.
72.
LucotJB. Effects of N-methyl-D-aspartate antagonists on different measures of motion sickness in cats. Brain Res Bull1998;47:407–11.
73.
DarlingtonCL, GilchristDP, SmithPF. Melanocortins and lesion-induced plasticity in the CNS: A review. Brain Res Brain Res Rev1996;22:245–57.
74.
GilchristDP, DarlingtonCL, SmithPF. Evidence that short ACTH fragments enhance vestibular compensation via direct action on the ipsilateral vestibular nucleus. Neuroreport1996;7:1489–92.
75.
StewartJJ, WoodMJ, WoodCD, MinisME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology1991;42:111–20.
